10th Edition of
World Congress on Infectious Diseases & One Health
October 05-07, 2026 | Tokyo, Japan
Antifungals represent a critical class of medications designed to combat fungal infections, offering relief from ailments caused by a diverse array of fungi. Azoles, such as fluconazole, interfere with fungal cell membrane synthesis, disrupting their structural integrity and impeding growth. Polyenes, like amphotericin B, bind to fungal cell membranes, causing membrane leakage and eventual cell death. Echinocandins, a newer class, inhibit the synthesis of fungal cell walls, curbing the progression of invasive fungal infections. Antifungals find applications in treating common conditions like athlete's foot and yeast infections, as well as more severe systemic infections such as candidiasis and aspergillosis. However, challenges persist, including the emergence of antifungal resistance, particularly in immunocompromised individuals. Ongoing research strives to unravel new antifungal targets and develop innovative strategies to address the dynamic landscape of fungal infections.
Title : Molecular crosstalk between the host and pathogen in Streptococcus pyogenes virulence
Francis J Castellino, University of Notre Dame, United States
Title : Phenotypic characterisation of non tuberculous mycobacterium species isolated from clinical specimens
Anant Marathe, Parul Institute of Medical Sciences and Research, Parul University, India
Title : Praziquantel for the treatment of preschool-aged children with schistosomiasis: Results of an RCT
Susannah Colt, Warren Alpert Medical School of Brown University, United States
Title : Carbapenemase-producing multidrug resistance of gram negative bacilli causing bacteremia at the general hospital of Mexico during the Covid-19 pandemic
Silvia Giono, Instituto Politecnico Nacional, Mexico
Title : The largest histamine poisoning outbreak in Brazil: An experience report from a one health perspective in Fernando de Noronha
Camila Ferro, Fundacao Oswaldo Cruz (Fiocruz), Brazil
Title : Combating antimicrobial resistance in sub-Saharan Africa: Advancing one health strategies for sustainable infectious disease control
Ugorji Miracle Enyinnaya, Greatlink Pharmaceutical, Nigeria